(S)-[(2S)-5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 英文名称: (S)-[(2S)-5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol
• 化学式: C20H25N2O+
• 分子量: 309.4
• InChiKey: IWPKILOVPZQFBF-NOGIUPJJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Process for the preparation of optically pure omeprazole via salt formation with a chiral amine
  申请人：KRKA, tovarna zdravil, d.d., Novo mesto

  公开号：EP2048144A1

  公开（公告）日：2009-04-15

  The present invention relates to a process for the preparation of substantially optically pure omeprazole, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to a process for preparing a pharmaceutical composition comprising the substantially optically pure omeprazole or the pharmaceutically acceptable salt or solvate thereof and to intermediates useful for the preparation of optically pure omeprazole.

  本发明涉及一种制备基本光学纯的奥美拉唑或其药用盐或溶剂的方法。本发明还涉及一种制备含基本光学纯的奥美拉唑或其药用盐或溶剂的制药组合物的方法，以及用于制备光学纯奥美拉唑的中间体。
• [EN] PROCESS FOR THE PREPARATION OF OPTICALLY PURE OMEPRAZOLE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'OMÉPRAZOLE OPTIQUEMENT PUR
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO

  公开号：WO2008092939A2

  公开（公告）日：2008-08-07

  [EN] The present invention relates to a process for the preparation of substantially optically pure omeprazole, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to a process for preparing a pharmaceutical composition comprising the substantially optically pure omeprazole or the pharmaceutically acceptable salt or solvate thereof and to intermediates useful for the preparation of optically pure omeprazole.
  [FR] La présente invention concerne un procédé de préparation d'oméprazole substantiellement optiquement pur, ou d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci. L'invention concerne également un procédé de préparation d'une composition pharmaceutique comprenant l'oméprazole substantiellement optiquement pur ou un sel ou un solvate pharmaceutiquement acceptable de celui-ci et des intermédiaires utiles pour la préparation d'oméprazole optiquement pur.